Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG01/QS-21 in KRAS/NRAS Mutated Multiple Myeloma
NCT05841550Phase 2Recruiting
- Sponsor
- Oslo University Hospital
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apricoxib in multiple myeloma (MM) and smoldering multiple myeloma (SMM), sponsored by Oslo University Hospital. Primary endpoints: Percentage of participants with adverse events and Percentage of participants discontinuing treatment secondary to treatment-related adverse events at 3 years. Started May 2023; status: recruiting.
02
Drugs
apricoxib
03
Conditions
multiple myeloma (MM)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT05841550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841550.